{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:54:56Z","timestamp":1788256496802,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004503","name":"Benha University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004503","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40256-024-00675-z","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T18:03:07Z","timestamp":1726077787000},"page":"775-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Efficacy and Safety of Levosimendan in Patients with Advanced Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-9750","authenticated-orcid":false,"given":"Ahmed Saad","family":"Elsaeidy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuelazm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Ghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mazen","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Gohary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Elshenawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amith Reddy","family":"Seri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Abdelazeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"675_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789\u2013858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"675_CR2","doi-asserted-by":"crossref","unstructured":"Sterling MR, Ringel JB, Pinheiro LC, Safford MM, Levitan EB, Phillips E, et al. Social determinants of health and 90-day mortality after hospitalization for heart failure in the regards study. J Am Heart Assoc. 2020;9.","DOI":"10.1161\/JAHA.119.014836"},{"key":"675_CR3","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143:e254-743.","journal-title":"Circulation"},{"key":"675_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jama.2012.339","volume":"307","author":"Q Yang","year":"2012","unstructured":"Yang Q, Cogswell ME, Dana Flanders W, Hong Y, Zhang Z, Loustalot F, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among us adults. JAMA. 2012;307:1273\u201383.","journal-title":"JAMA"},{"key":"675_CR5","doi-asserted-by":"publisher","unstructured":"The efficacy and safety of new potassium binders on renin\u2013angiotensin\u2013aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta\u2010analysis\u2014Abuelazm\u20142024\u2014ESC Heart Failure\u2014Wiley Online Library [Internet]. https:\/\/doi.org\/10.1002\/ehf2.14588. Cited 19 Mar 2024.","DOI":"10.1002\/ehf2.14588"},{"key":"675_CR6","doi-asserted-by":"crossref","unstructured":"Repetitive LevosimenDan infusions fOR patients with advanced chronic heart failure in the vulnerable post-discharge period: the multinational randomized LeoDOR trial. Eur Heart J Oxford Academic [Internet]. https:\/\/academic.oup.com\/eurheartj\/article\/44\/Supplement_2\/ehad655.798\/7391695. Cited 9 Dec 2023.","DOI":"10.1093\/eurheartj\/ehad655.798"},{"key":"675_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/jcm9020373","volume":"9","author":"E Grossini","year":"2020","unstructured":"Grossini E, Farruggio S, Pierelli D, Bolzani V, Rossi L, Pollesello P, et al. Levosimendan improves oxidative balance in cardiogenic shock\/low cardiac output patients. J Clin Med. 2020;9:373.","journal-title":"J Clin Med"},{"key":"675_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10557-018-6838-2","volume":"32","author":"S Bouchez","year":"2018","unstructured":"Bouchez S, Fedele F, Giannakoulas G, Gustafsson F, Harjola VP, Karason K, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018;32:617\u201324.","journal-title":"Cardiovasc Drugs Ther"},{"key":"675_CR9","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.jacc.2014.01.016","volume":"63","author":"GS Francis","year":"2014","unstructured":"Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol. 2014;63:2069\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"675_CR10","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","volume":"36","author":"MS Nieminen","year":"2000","unstructured":"Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"675_CR11","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1136\/hrt.2005.079707","volume":"92","author":"JT Parissis","year":"2006","unstructured":"Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. 2006;92:1768\u201372.","journal-title":"Heart"},{"key":"675_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","volume":"1","author":"M Packer","year":"2013","unstructured":"Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103\u201311.","journal-title":"JACC Heart Fail."},{"key":"675_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.amjcard.2005.03.092","volume":"96","author":"JT Parissis","year":"2005","unstructured":"Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, et al. Effects of Levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005;96:423\u20136.","journal-title":"Am J Cardiol"},{"key":"675_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1388-9842(02)00041-7","volume":"4","author":"S Thackray","year":"2002","unstructured":"Thackray S, Easthaugh J, Freemantle N, Cleland JGF. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure\u2014a meta-regression analysis. Eur J Heart Fail. 2002;4:515\u201329.","journal-title":"Eur J Heart Fail"},{"key":"675_CR15","unstructured":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Cardiology. JAMA. JAMA Network [Internet]. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/194768. Cited 28 Mar 2024."},{"key":"675_CR16","doi-asserted-by":"publisher","unstructured":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study\u2014Garc\u00eda\u2010Gonz\u00e1lez\u20142021\u2014ESC heart failure\u2014Wiley Online Library [Internet]. https:\/\/doi.org\/10.1002\/ehf2.13670. Cited 9 Dec 2023.","DOI":"10.1002\/ehf2.13670"},{"key":"675_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00380-009-1216-4","volume":"25","author":"IH Kurt","year":"2010","unstructured":"Kurt IH, Yavuzer K, Batur MK. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure. Heart Vessels. 2010;25:392\u20139.","journal-title":"Heart Vessels"},{"key":"675_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","volume":"9","author":"J Lilleberg","year":"2007","unstructured":"Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75\u201382.","journal-title":"Eur J Heart Fail"},{"key":"675_CR19","first-page":"268","volume":"24","author":"P Llorens","year":"2012","unstructured":"Llorens P, Miro O, Roman F, Zapater P, Carbajosa-Dalmau J, Llanos L. Efficacy of early administration of levosimendan in emergency department in patients with acute heart failure: a randomized pilot clinical trial. Emergencias. 2012;24:268\u201376.","journal-title":"Emergencias."},{"key":"675_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cardfail.2007.04.004","volume":"13","author":"S Mavrogeni","year":"2007","unstructured":"Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail. 2007;13:556\u20139.","journal-title":"J Card Fail"},{"key":"675_CR21","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.ejheart.2008.09.006","volume":"10","author":"MS Nieminen","year":"2008","unstructured":"Nieminen MS, Cleland JGF, Eha J, Belenkov Y, Kivikko M, P\u00f5der P, et al. Oral levosimendan in patients with severe chronic heart failure\u2014the PERSIST study. Eur J Heart Fail. 2008;10:1246\u201354.","journal-title":"Eur J Heart Fail"},{"key":"675_CR22","doi-asserted-by":"publisher","unstructured":"Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients. Cardiovasc Drugs Ther. [Internet]. https:\/\/doi.org\/10.1007\/s10557-007-6034-2. Cited 9 Dec 2023.","DOI":"10.1007\/s10557-007-6034-2"},{"key":"675_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/0253-7613.125161","volume":"46","author":"B Shah","year":"2014","unstructured":"Shah B, Sharma P, Brahmbhatt A, Shah R, Rathod B, Shastri N, et al. Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian J Pharmacol. 2014;46:29\u201334.","journal-title":"Indian J Pharmacol."},{"key":"675_CR24","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.12659\/MSM.893580","volume":"21","author":"D Zhang","year":"2015","unstructured":"Zhang D, Yao Y, Qian J, Huang J. Levosimendan improves clinical outcomes of refractory heart failure in elderly chinese patients. Med Sci Monit. 2015;21:2439\u201345.","journal-title":"Med Sci Monit"},{"key":"675_CR25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","volume":"20","author":"J Com\u00edn-Colet","year":"2018","unstructured":"Com\u00edn-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garc\u00eda Pinilla JM, Almenar L, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20:1128\u201336.","journal-title":"Eur J Heart Fail"},{"key":"675_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5830\/CVJA-2020-008","volume":"31","author":"XR Cui","year":"2020","unstructured":"Cui XR, Yang XH, Li RB, Wang D, Jia M, Bai L, et al. Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure. Cardiovasc J Afr. 2020;31:196\u2013200.","journal-title":"Cardiovasc J Afr"},{"key":"675_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ejhf.118","volume":"16","author":"J Altenberger","year":"2014","unstructured":"Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014;16:898\u2013906.","journal-title":"Eur J Heart Fail"},{"key":"675_CR28","unstructured":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. https:\/\/www.bmj.com\/content\/372\/bmj.n71. Cited 9 Dec 2023."},{"key":"675_CR29","unstructured":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/31643080\/. Cited 9 Dec 2023."},{"key":"675_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"675_CR31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ. What is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ. 2008;336:995\u20138.","journal-title":"BMJ"},{"key":"675_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"675_CR33","unstructured":"Collaboration C. Review Manager (RevMan)[Computer program]. Version 5.3. 5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. The; 2014."},{"key":"675_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/diseases11040183","volume":"11","author":"M Abuelazm","year":"2023","unstructured":"Abuelazm M, Ali S, AlBarakat MM, Mahmoud A, Tanashat M, Suilik HA, et al. Istaroxime for patients with acute heart failure: a systematic review and meta-analysis of randomized controlled trials. Diseases. 2023;11:183.","journal-title":"Diseases"},{"key":"675_CR35","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: cochrane book series."},{"key":"675_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17:39.","journal-title":"BMC Med Res Methodol"},{"key":"675_CR37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12872-024-03917-9","volume":"24","author":"AS Elsaeidy","year":"2024","unstructured":"Elsaeidy AS, Taha AM, Abuelazm M, Soliman Y, Ali MA, Alassiri AK, et al. Efficacy and safety of extracorporeal membrane oxygenation for cardiogenic shock complicating myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24:362.","journal-title":"BMC Cardiovasc Disord"},{"key":"675_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ejhf.3081","volume":"26","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni D, Pagnesi M, Colombo G, Chiarito M, Stolfo D, Baldetti L, et al. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry. Eur J Heart Fail. 2024;26:327\u201337.","journal-title":"Eur J Heart Fail"},{"key":"675_CR39","unstructured":"Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis\u2014PMC [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6119101\/. Cited 8 Mar 2024."},{"key":"675_CR40","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-1032.","journal-title":"Circulation"},{"key":"675_CR41","doi-asserted-by":"publisher","unstructured":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med [Internet]. https:\/\/doi.org\/10.1056\/NEJMoa2025797. Cited 2 Aug 2024.","DOI":"10.1056\/NEJMoa2025797"},{"key":"675_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10741-021-10101-0","volume":"27","author":"H Elsherbini","year":"2022","unstructured":"Elsherbini H, Soliman O, Zijderhand C, Lenzen M, Hoeks SE, Kaddoura R, et al. Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure: a systematic review and meta-analysis of 984 patients. Heart Fail Rev. 2022;27:493\u2013505.","journal-title":"Heart Fail Rev"},{"key":"675_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40256-020-00416-y","volume":"21","author":"D Cui","year":"2021","unstructured":"Cui D, Liao Y, Li G, Chen Y. Levosimendan can improve the level of B-type natriuretic peptide and the left ventricular ejection fraction of patients with advanced heart failure: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2021;21:73\u201381.","journal-title":"Am J Cardiovasc Drugs"},{"key":"675_CR44","doi-asserted-by":"publisher","first-page":"24097","DOI":"10.1038\/s41598-021-03317-5","volume":"11","author":"Y Hu","year":"2021","unstructured":"Hu Y, Wei Z, Zhang C, Lu C, Zeng Z. The effect of levosimendan on right ventricular function in patients with heart dysfunction: a systematic review and meta-analysis. Sci Rep. 2021;11:24097.","journal-title":"Sci Rep"},{"key":"675_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008706","volume":"15","author":"CJ Kapelios","year":"2022","unstructured":"Kapelios CJ, Lund LH, Wever-Pinzon O, Selzman CH, Myers SL, Cantor RS, et al. Right heart failure following left ventricular device implantation: natural history, risk factors, and outcomes: an analysis of the STS INTERMACS database. Circ Heart Fail. 2022;15: e008706.","journal-title":"Circ Heart Fail"},{"key":"675_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008455","volume":"7","author":"L Lannemyr","year":"2018","unstructured":"Lannemyr L, Ricksten S-E, Rundqvist B, Andersson B, Bartfay S-E, Ljungman C, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment:a randomized double-blind controlled trial. J Am Heart Assoc. 2018;7: e008455.","journal-title":"J Am Heart Assoc"},{"key":"675_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10557-007-6066-7","volume":"21","author":"MB Yilmaz","year":"2007","unstructured":"Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431\u20135.","journal-title":"Cardiovasc Drugs Ther"},{"key":"675_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cardfail.2007.03.005","volume":"13","author":"G Zemljic","year":"2007","unstructured":"Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail. 2007;13:417\u201321.","journal-title":"J Card Fail"},{"key":"675_CR49","first-page":"795","volume":"33","author":"N Moreno","year":"2014","unstructured":"Moreno N, Tavares-Silva M, Louren\u00e7o AP, Oliveira-Pinto J, Henriques-Coelho T, Leite-Moreira AF. Levosimendan: The current situation and new prospects. Rev Port Cardiol Orgao Of Soc Port Cardiol Port J Cardiol Off J Port Soc Cardiol. 2014;33:795\u2013800.","journal-title":"Rev Port Cardiol Orgao Of Soc Port Cardiol Port J Cardiol Off J Port Soc Cardiol."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00675-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00675-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00675-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:30:41Z","timestamp":1730305841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00675-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["675"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00675-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"19 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.A., B.P. and C.B. conceived the idea. B.A., A.S.E. and M.A. designed the research workflow. B.A. and M.A. searched the databases. A.M.A., M.E., S.E. and A.R.S. screened the retrieved records, extracted relevant data, assessed the quality of evidence, and B.A.\u00a0and A.S.E resolved the conflicts. Y.S. performed the analysis. R.G., Y.S. and A.S.E. wrote the final manuscript. B.A., B.P., and C.B. supervised the project. All authors have read and agreed to the final version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We received no funding for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}]}}